title: The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: an in vivo study.
abstract: Selenium salts as well as elemental selenium nanoparticles are attracting the attention of researchers due to their excellent biological properties. The aim of the present work was to study immunomodulation by applying elemental Se NPs to stimulate the immune response of mice bearing 4 T1 breast cancer tumors. Six- to 8-week-old female inbred BALB/c mice were divided into two groups of test and control, each containing 15 mice. Every day, for 2 weeks prior to tumor induction, selenium nanoparticles were orally administered to the mice at a dose of 100 μg/day. Then, 1 × 10(6) cells from a 4 T1 cell line were injected subcutaneously to each mouse. Oral nanoparticle administration was continued daily for 3 weeks after tumor induction. Different immunological parameters were then evaluated including cytokine level, delayed type hypersensitivity (DTH) response as well as tumor growth and the survival rates in all treated or nontreated animals. The production of Th1 cytokines, such as IFN-γ and IL-12, in spleen cell culture was increased in the test mice-administered selenium nanoparticles. The DTH response of test mice also showed a significant increase when compared to the control mice. The survival rate was notably higher for the selenium nanoparticle-treated mice compared to the control mice. Our results suggest that selenium nanoparticle administration can result in considerable induction of the Th1 platform of immune response through the elevation of IFN-γ and IL-12 and may be a cause for better prognosis in mice with tumors.
authors.affiliation: Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Mohammad Hossein
authors.initials: MH
authors.lastname: Yazdi
authors.forename: Mehdi
authors.initials: M
authors.lastname: Mahdavi
authors.forename: Bardia
authors.initials: B
authors.lastname: Varastehmoradi
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Faramarzi
authors.forename: Ahmad Reza
authors.initials: AR
authors.lastname: Shahverdi
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D005260:Female; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007111:Immunity, Cellular; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D007371:Interferon-gamma / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage* / Q000627:therapeutic use; D012643:Selenium / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D007155:Immunologic Factors; D018664:Interleukin-12; D007371:Interferon-gamma; D012643:Selenium